4-Antibody AG Meets Next Milestone in Boehringer Ingelheim Collaboration
4-Antibody AG announced the successful completion of a second milestone in its ongoing collaboration with Boehringer Ingelheim. This second milestone triggered an undisclosed fee payment.
4-Antibody’s R&D collaboration with Boehringer Ingelheim commenced in early 2010 and is a long-term collaboration to discover and develop fully human therapeutic antibodies for a number of targets in various disease indications. The collaboration centres on 4-Antibody’s proprietary high throughput in vitro Retrocyte Display® technology for rapid antibody discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim.
Robert Burns, 4-Antibody’s CEO, said: “Not only do you want your collaborations to serve an important role in validating your technology, but you also want your partners to be sufficiently happy that they continue to pay milestone payments as successful programme targets are achieved. We set out with our high throughput in vitro Retrocyte Display® technology to show we can take all the advantages of in vivo as well as in vitro platforms and combine them both without the limitations of these existing approaches. We see our continued partnering success as confirmation of that strategy.”
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous